Compare Axon Enterprise Inc (AXON) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Inovio Pharmaceuticals Inc — how do they compare? Axon Enterprise Inc trades at $539.75 (market cap $44.11B), while Inovio Pharmaceuticals Inc trades at $1.17 (market cap $95.85M). The key difference: Axon Enterprise Inc is far larger — about 460.2× Inovio Pharmaceuticals Inc's market cap, and Axon Enterprise Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AXON | INO | |
|---|---|---|
Market Cap | $44.11B | $95.85M |
Sector | Technology | Health |
52-Week High | $870.97 | $2.87 |
52-Week Low | $345.94 | $1.05 |
Enterprise Value | $45.20B | $66.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $547.03, down 3.32% on the day, with strong analyst support (81% buy ratings) and a consensus price target of $648.67. The stock shows bullish technical signals with support at $539 and resistance at $553. Recent earnings have been mixed with Q3 2025 missing estimates but Q4 2025 and Q1 2026 beating expectations. Revenue growth remains solid with 2026 projections at $3.0B and net profit margin improving to 6.9%.
Axon presents growth potential driven by strong demand for connected devices and software services, though elevated valuation ratios (P/E 220.67) pose risk. Positive sentiment stems from recent upgrades and institutional interest, including notable insider buying. Key risks include execution challenges and competitive pressures in the law enforcement technology sector.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
